Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
The European Medicines Agency's CHMP has adopted a positive opinion for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer in patients ineligible for PD-(L)1 inhibitors. This recommendation is based on the Phase 3 ASCENT-03 study, which showed a 38% reduction in the risk of disease progression or death compared to standard chemotherapy. Gilead has also submitted a corresponding application to the U.S. FDA for this indication, with a decision anticipated later in 2026.
Key figures
- Drug Name
- Trodelvy (sacituzumab govitecan-hziy)
- Phase Of Trial
- Phase 3
- Patients treated
- 75000
- Countries approved
- 60
- Risk reduction pct
- 38
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.